title: [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
abstract: Eight patients with acute non-lymphocytic leukemia in adults refractory to Daunomycin (DM)-based conventional regimens were treated with AMSA-based regimens. Complete remission (CR) was obtained in 4 (50%) and partial remission (PR) in 2 (25%). The median time to CR was 26.5 days and 3 cases achieved CR in the first cycle. The median duration of CR was 8.3 months. Hematologic toxicity was severe and the nadir (median) of leukocytes and platelets was 0.15 x 10(3)/microliters and 15.5 x 10(3)/microliters, respectively. Other adverse effects were mucositis, nausea.vomiting and hepatotoxicity which occurred over 50%, while cardiac toxicity was not observed. This study indicates that AMSA is clinically non-cross-resistant to DM and considered to be an active drug for salvage therapy.
authors.affiliation: Dept. of Clinical Oncology, Cancer Institute Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Mukaiyama
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
authors.forename: N
authors.initials: N
authors.lastname: Horikoshi
authors.forename: K
authors.initials: K
authors.lastname: Inoue
authors.forename: H
authors.initials: H
authors.lastname: Fukutani
authors.forename: M
authors.initials: M
authors.lastname: Tabata
authors.forename: A
authors.initials: A
authors.lastname: Hirano
authors.forename: N
authors.initials: N
authors.lastname: Mizunuma
authors.forename: S
authors.initials: S
authors.lastname: Itami
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000677:Amsacrine / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003630:Daunorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D011239:Prednisolone; C015019:enocitabine; D013866:Thioguanine; D003630:Daunorubicin